Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Malignant Melanoma

  Free Subscription

Articles published in J Invest Dermatol

Retrieve available abstracts of 131 articles:
HTML format

Single Articles

    June 2020
  1. WANG P, Li Y, Ma Y, Zhang X, et al
    Comprehensive investigation into the role of ubiquitin conjugating enzyme E2S (UBE2S) in melanoma development.
    J Invest Dermatol. 2020 Jun 27. pii: S0022-202X(20)31729.
    PubMed     Abstract available

    May 2020
  2. TRUCCO LD, Mundra PA, Garcia-Martinez P, Hogan K, et al
    Map3k1 Loss Cooperates With Braf(V600E) to Drive Melanomagenesis.
    J Invest Dermatol. 2020 May 22. pii: S0022-202X(20)31598.

  3. NGUYEN MQ, Teh JLF, Purwin TJ, Chervoneva I, et al
    Targeting PHGDH upregulation reduces glutathione levels and re-sensitizes resistant NRAS mutant melanoma to MEK inhibition.
    J Invest Dermatol. 2020 May 7. pii: S0022-202X(20)31406.
    PubMed     Abstract available

  4. ADAM C, Fusi L, Weiss N, Goller SG, et al
    Efficient suppression of NRAS-driven melanoma by co-inhibition of ERK1/2 and ERK5 MAPK pathways.
    J Invest Dermatol. 2020 May 3. pii: S0022-202X(20)31407.
    PubMed     Abstract available

    April 2020
  5. AVITAN-HERSH E, Feng Y, Vaisman AO, Ahmed YA, et al
    Regulation of eIF2alpha by RNF4 promotes melanoma tumorigenesis and therapy resistance.
    J Invest Dermatol. 2020 Apr 29. pii: S0022-202X(20)31404.
    PubMed     Abstract available

  6. TIFFEN J, Gallagher S, Filipp F, Gunatilake D, et al
    EZH2 cooperates with DNA methylation to downregulate key tumour suppressors and interferon gene signatures in melanoma.
    J Invest Dermatol. 2020 Apr 29. pii: S0022-202X(20)31390.
    PubMed     Abstract available

  7. CHAVEZ A, Quesenberry CP Jr, Darbinian J, Asgari MM, et al
    Association of valproic acid use, a potent histone deacetylase inhibitor, and melanoma risk.
    J Invest Dermatol. 2020 Apr 27. pii: S0022-202X(20)31402.
    PubMed     Abstract available

  8. GUO Y, Zhang X, Zeng W, Zhang J, et al
    TRAF6 activates fibroblasts to cancer-associated fibroblasts (CAFs) through FGF19 in tumor microenvironment to benefit the malignant phenotype of melanoma cells.
    J Invest Dermatol. 2020 Apr 7. pii: S0022-202X(20)31352.
    PubMed     Abstract available

  9. KUNG FF, Arias-Mejias SM, Quattrocchi E, Sominidi-Damodaran S, et al
    PD-1, PD-L1 and BIM as predictors of sentinel lymph node metastasis in primary cutaneous melanoma.
    J Invest Dermatol. 2020 Apr 7. pii: S0022-202X(20)31349.

  10. DIKA E, Riefolo M, Porcellini E, Broseghini E, et al
    Defining the prognostic role of microRNAs in cutaneous melanoma.
    J Invest Dermatol. 2020 Apr 7. pii: S0022-202X(20)31351.
    PubMed     Abstract available

  11. JENKINS RW, Fisher DE
    Treatment of Advanced Melanoma in 2020 and Beyond.
    J Invest Dermatol. 2020 Apr 5. pii: S0022-202X(20)31257.
    PubMed     Abstract available

  12. JOSHI SS, Hornyak TJ
    Cellular Phenotypic Plasticity of Cutaneous Melanoma: A Complex Puzzle.
    J Invest Dermatol. 2020;140:743-745.
    PubMed     Abstract available

    March 2020
  13. CHRISTODOULOU E, Nell RJ, Verdijk RM, Gruis NA, et al
    Loss of wild-type CDKN2A is an early event in the development of melanoma in FAMMM syndrome.
    J Invest Dermatol. 2020 Mar 28. pii: S0022-202X(20)31205.

    February 2020
  14. VESELY MD, Chen L
    Normalization Cancer Immunotherapy for Melanoma.
    J Invest Dermatol. 2020 Feb 21. pii: S0022-202X(20)30153.
    PubMed     Abstract available

  15. CHANG GA, Wiggins JM, Corless BC, Syeda MM, et al
    TERT, BRAF, and NRAS mutational heterogeneity between paired primary and metastatic melanoma tumors.
    J Invest Dermatol. 2020 Feb 19. pii: S0022-202X(20)30159.
    PubMed     Abstract available

  16. PATEL S, Wilkinson CJ, Sviderskaya EV
    Loss of both CDKN2A and CDKN2B allows for centrosome overduplication in melanoma.
    J Invest Dermatol. 2020 Feb 14. pii: S0022-202X(20)30147.
    PubMed     Abstract available

    January 2020
  17. GUO D, Jain R, Hwang JS, Weninger W, et al
    RAB27A/Melanophilin blocker inhibits melanoma cell motility and invasion.
    J Invest Dermatol. 2020 Jan 21. pii: S0022-202X(20)30036.

  18. BRAUN AD, Mengoni M, Bonifatius S, Tuting T, et al
    Activated Hgf-Met signaling cooperates with oncogenic Braf to drive primary cutaneous melanomas and angiotropic lung metastases in mice.
    J Invest Dermatol. 2020 Jan 20. pii: S0022-202X(20)30019.
    PubMed     Abstract available

  19. HONG CH, Ho JC, Lee CH
    Steroid receptor RNA activator (SRA), a long noncoding RNA, activates p38, facilitates epithelial mesenchymal transformation, and experimental melanoma metastasis.
    J Invest Dermatol. 2020 Jan 13. pii: S0022-202X(19)33503.
    PubMed     Abstract available

  20. SHELLMAN MH, Shellman YG
    Human against Machine? Machine Learning Identifies MicroRNA Ratios as Biomarkers for Melanoma.
    J Invest Dermatol. 2020;140:18-20.
    PubMed     Abstract available

    December 2019
  21. BARCELO C, Siso P, Maiques O, Garcia-Mulero S, et al
    T-Type calcium channels as potential therapeutic targets in vemurafenib-resistant BRAF(V600E) melanoma: TTCCs are therapy target in BRAF(V600E) melanoma.
    J Invest Dermatol. 2019 Dec 23. pii: S0022-202X(19)33497.
    PubMed     Abstract available

    November 2019
  22. LIU X, Mi J, Qin H, Li Z, et al
    E2F1/IGF-1R loop contributes to BRAF inhibitor resistance in melanoma.
    J Invest Dermatol. 2019 Nov 6. pii: S0022-202X(19)33385.

    October 2019
  23. WENZINA J, Holzner S, Puujalka E, Cheng PF, et al
    Inhibition of p38/MK2 signaling prevents vascular invasion of melanoma.
    J Invest Dermatol. 2019 Oct 14. pii: S0022-202X(19)33299.
    PubMed     Abstract available

  24. ZENG H, Judson-Torres RL, Shain AH
    The Evolution of Melanoma - Moving beyond Binary Models of Genetic Progression.
    J Invest Dermatol. 2019 Oct 14. pii: S0022-202X(19)32699.
    PubMed     Abstract available

    September 2019
  25. GIBBS DC, Orlow I, Vernali S, Powell HB, et al
    Inherited Melanoma Risk Variants Associated with Histopathologically Amelanotic Melanoma.
    J Invest Dermatol. 2019 Sep 27. pii: S0022-202X(19)33239.

    August 2019
  26. ZHU G, Xu P, Guo S, Yi X, et al
    Metastatic melanoma cells rely on Sestrin2 to acquire anoikis resistance via detoxifying intracellular ROS.
    J Invest Dermatol. 2019 Aug 30. pii: S0022-202X(19)33208.
    PubMed     Abstract available

  27. TORRES R, Lang UE, Hejna M, Shelton SJ, et al
    MicroRNA ratios distinguish melanomas from nevi.
    J Invest Dermatol. 2019 Aug 22. pii: S0022-202X(19)31788.
    PubMed     Abstract available

  28. HARDIE CM, Elliott F, Chan M, Rogers Z, et al
    Environmental exposures such as smoking and low vitamin D are predictive of poor outcome in cutaneous melanoma rather than other deprivation measures.
    J Invest Dermatol. 2019 Aug 16. pii: S0022-202X(19)32703.
    PubMed     Abstract available

  29. SHAUGHNESSY M, Njauw CN, Artomov M, Tsao H, et al
    Classifying melanoma by TERT promoter mutational status.
    J Invest Dermatol. 2019 Aug 16. pii: S0022-202X(19)32704.
    PubMed     Abstract available

  30. HANOUNA G, Tang E, Perez J, Vandermeersch S, et al
    Preventing Calpain Externalization by Reducing ABCA1 Activity with Probenecid Limits Melanoma Angiogenesis and Development.
    J Invest Dermatol. 2019 Aug 16. pii: S0022-202X(19)32702.
    PubMed     Abstract available

  31. DUFFY DL, Jagirdar K, Lee KJ, McWhirter SR, et al
    Genes determining nevus count and dermoscopic appearance in Australian melanoma cases and controls.
    J Invest Dermatol. 2019 Aug 14. pii: S0022-202X(19)32695.

  32. ZHOU S, Liang Y, Zhang X, Liao L, et al
    SHARPIN Promotes Melanoma Progression via Rap1 Signaling Pathway.
    J Invest Dermatol. 2019 Aug 8. pii: S0022-202X(19)32683.
    PubMed     Abstract available

    July 2019
  33. LEACHMAN SA, Hornyak TJ, Barsh G, Bastian BC, et al
    Melanoma to Vitiligo: The Melanocyte in Biology & Medicine-Joint Montagna Symposium on the Biology of Skin/PanAmerican Society for Pigment Cell Research Annual Meeting.
    J Invest Dermatol. 2019 Jul 23. pii: S0022-202X(19)32550.

  34. SARGEN MR, Pfeiffer RM, Yang XR, Tucker MA, et al
    Variation in cutaneous patterns of melanomagenesis according to germline CDKN2A/CDK4 status in melanoma-prone families.
    J Invest Dermatol. 2019 Jul 18. pii: S0022-202X(19)32536.
    PubMed     Abstract available

  35. AIRA LE, Debes GF
    B Cells and Melanoma Pathogenesis.
    J Invest Dermatol. 2019;139:1422-1424.
    PubMed     Abstract available

    June 2019
  36. VOGEL FCE, Bordag N, Zugner E, Trajkovic-Arsic M, et al
    Targeting the H3K4 demethylase KDM5B reprograms the metabolome and phenotype of melanoma cells.
    J Invest Dermatol. 2019 Jun 20. pii: S0022-202X(19)31782.
    PubMed     Abstract available

  37. FANG S, Xu T, Xiong M, Zhou X, et al
    Role of immune response, inflammation and tumor immune response-related cytokines/chemokines in melanoma progression.
    J Invest Dermatol. 2019 Jun 6. pii: S0022-202X(19)31626.
    PubMed     Abstract available

    May 2019
  38. KOOPMANS I, Hendriks MAJM, van Ginkel RJ, Samplonius DF, et al
    Bispecific antibody approach for improved melanoma-selective PD-L1 immune checkpoint blockade.
    J Invest Dermatol. 2019 May 22. pii: S0022-202X(19)31565.
    PubMed     Abstract available

    March 2019
  39. TAKABE P, Karna R, Rauhala L, Tammi M, et al
    Melanocyte hyaluronan coat fragmentation enhances the UVB-induced TLR-4 receptor signaling and expression of proinflammatory mediators IL-6, IL-8, CXCL-1 and CXCL-10 via NF-kappaB activation.
    J Invest Dermatol. 2019 Mar 29. pii: S0022-202X(19)31391.
    PubMed     Abstract available

  40. SANA G, Madigan JP, Gartner JJ, Fourrez M, et al
    Exome sequencing of ABCB5 identifies recurrent melanoma mutations that result in increased proliferative and invasive capacities.
    J Invest Dermatol. 2019 Mar 21. pii: S0022-202X(19)31330.
    PubMed     Abstract available

  41. KOBAYASHI T, Oishi K, Okamura A, Shintaro M, et al
    Regulatory B1a cells suppress melanoma tumor immunity via IL-10 production and inhibiting Th1 cytokine production in tumor-infiltrating CD8(+) T cells.
    J Invest Dermatol. 2019 Mar 2. pii: S0022-202X(19)30186.
    PubMed     Abstract available

  42. MCKEAN M, Oba J, Ma J, Roth KG, et al
    Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma.
    J Invest Dermatol. 2019;139:728-731.

    February 2019
  43. DAVIDSON G, Coassolo S, Kieny A, Ennen M, et al
    Dynamic evolution of clonal composition and neoantigen landscape in recurrent metastatic melanoma with a rare combination of driver mutations.
    J Invest Dermatol. 2019 Feb 15. pii: S0022-202X(19)30108.
    PubMed     Abstract available

    January 2019
  44. ZHANG X, Peng Y, Li C, Li Q, et al
    Genomic heterogeneity and branched evolution of early-stage primary acral melanoma revealed by multi-regional microdissection sequencing.
    J Invest Dermatol. 2019 Jan 30. pii: S0022-202X(19)30045.
    PubMed     Abstract available

  45. NIKBAKHT N, Tiago M, Erkes DA, Chervoneva I, et al
    BET inhibition modifies melanoma infiltrating T cells and enhances response to PD-L1 blockade.
    J Invest Dermatol. 2019 Jan 28. pii: S0022-202X(19)30026.

  46. INOZUME T, Yaguchi T, Ariyasu R, Togashi Y, et al
    Analysis of the tumor reactivity of tumor-infiltrating lymphocytes in a metastatic melanoma lesion that lost MHC class I expression after anti-PD-1 therapy.
    J Invest Dermatol. 2019 Jan 23. pii: S0022-202X(19)30023.
    PubMed     Abstract available

  47. SHIN SY, Choi JH, Jung E, Gil HN, et al
    The EGR1-STAT3 Transcription Factor Axis Regulates alpha-MSH-induced Tyrosinase Gene Transcription in Melanocytes.
    J Invest Dermatol. 2019 Jan 12. pii: S0022-202X(19)30010.

  48. AVIGAD LARON E, Aamar E, Enshell-Seijffers D
    The Serine Protease Activity of Corin Is Required for Normal Pigment Type Switching.
    J Invest Dermatol. 2019;139:257-259.

    December 2018
  49. OLSEN CM, Green AC, Pandeya N, Whiteman DC, et al
    Trends in melanoma incidence rates in eight susceptible populations to 2015.
    J Invest Dermatol. 2018 Dec 19. pii: S0022-202X(18)30008.

  50. MILES JA, Orlow I, Kanetsky PA, Luo L, et al
    Relationship of Chromosome Arm 10q Variants to Occurrence of Multiple Primary Melanoma in the Population-Based GEM Study.
    J Invest Dermatol. 2018 Dec 17. pii: S0022-202X(18)32938.

  51. MURER P, Kiefer JD, Pluss L, Matasci M, et al
    Targeted delivery of TNF potentiates the antibody-dependent cell-mediated cytotoxicity of an anti-melanoma immunoglobulin.
    J Invest Dermatol. 2018 Dec 10. pii: S0022-202X(18)32928.
    PubMed     Abstract available

  52. CONWAY K, Edmiston SN, Parker JS, Kuan PF, et al
    Identification of a robust methylation classifier for cutaneous melanoma diagnosis.
    J Invest Dermatol. 2018 Dec 6. pii: S0022-202X(18)32916.
    PubMed     Abstract available

    November 2018
  53. FERRIS L, Moy R, Gerami P, Sligh JE, et al
    Non-Invasive Analysis of High-Risk Driver Mutations and Gene Expression Profiles in Primary Cutaneous Melanoma.
    J Invest Dermatol. 2018 Nov 27. pii: S0022-202X(18)32894.
    PubMed     Abstract available

  54. ATKINSON A, Renziehausen A, Wang H, Lo Nigro C, et al
    The collagen prolyl hydroxylases are bifunctional growth regulators in melanoma.
    J Invest Dermatol. 2018 Nov 16. pii: S0022-202X(18)32822.
    PubMed     Abstract available

  55. KIMLIN MG, Youlden DR, Brodie AM, DiSipio T, et al
    Risk of second primary cancer in survivors of in situ melanoma.
    J Invest Dermatol. 2018 Nov 10. pii: S0022-202X(18)32804.
    PubMed     Abstract available

    October 2018
  56. AMSCHLER K, Beyazpinar I, Erpenbeck L, Kruss S, et al
    Morphological Plasticity of Human Melanoma Cells is Determined by Nanoscopic Patterns of E- and N-Cadherin Interactions.
    J Invest Dermatol. 2018 Oct 27. pii: S0022-202X(18)32710.
    PubMed     Abstract available

  57. PETRIE T, Samatham R, Witkowski AM, Esteva A, et al
    Melanoma Early Detection: Big Data, Bigger Picture.
    J Invest Dermatol. 2018 Oct 25. pii: S0022-202X(18)32354.
    PubMed     Abstract available

  58. OLSEN CM, Pandeya N, Thompson BS, Dusingize JC, et al
    Association between phenotypic characteristics and melanoma in a large prospective cohort study.
    J Invest Dermatol. 2018 Oct 24. pii: S0022-202X(18)32692.
    PubMed     Abstract available

    August 2018
  59. GILES KM, Rosenbaum BE, Berger M, Izsak A, et al
    Revisiting the clinical and biologic relevance of partial PTEN loss in melanoma.
    J Invest Dermatol. 2018 Aug 24. pii: S0022-202X(18)32503.
    PubMed     Abstract available

  60. PAMPENA R, Pellacani G, Longo C
    Nevus-Associated Melanoma: Patient Phenotype and Potential Biological Implications.
    J Invest Dermatol. 2018;138:1696-1698.
    PubMed     Abstract available

  61. SAHOO A, Sahoo SK, Joshi P, Lee B, et al
    MicroRNA-211 loss promotes metabolic vulnerability and BRAF inhibitor sensitivity in melanoma.
    J Invest Dermatol. 2018 Aug 1. pii: S0022-202X(18)32458.
    PubMed     Abstract available

    July 2018
  62. RAMSPOTT JP, Bekkat F, Bod L, Favier M, et al
    Emerging role of IL4-induced gene 1 as a prognostic biomarker affecting the local T cell response in human cutaneous melanoma.
    J Invest Dermatol. 2018 Jul 23. pii: S0022-202X(18)32301.
    PubMed     Abstract available

  63. NOSRATI A, Yu WY, McGuire J, Griffin A, et al
    Outcomes and risk factors in patients with multiple primary melanomas.
    J Invest Dermatol. 2018 Jul 19. pii: S0022-202X(18)32359.
    PubMed     Abstract available

  64. ZHANG K, Anumanthan G, Scheaffer S, Cornelius LA, et al
    HMGB1/RAGE Mediates UVB-induced Secretory Inflammatory Response and Resistance to Apoptosis in Human Melanocytes.
    J Invest Dermatol. 2018 Jul 17. pii: S0022-202X(18)32348.
    PubMed     Abstract available

  65. FORSTHUBER A, Lipp K, Andersen L, Ebersberger S, et al
    CXCL5 as regulator of neutrophil function in cutaneous melanoma.
    J Invest Dermatol. 2018 Jul 13. pii: S0022-202X(18)32353.
    PubMed     Abstract available

  66. TAKAISHI M, Sano S
    Transdifferentiation of melanoma cells by the reprogramming factors attenuates malignant nature in vitro and in vivo.
    J Invest Dermatol. 2018 Jul 7. pii: S0022-202X(18)32303.

    June 2018
  67. CUST AE, Drummond M, Kanetsky PA, Goldstein AM, et al
    Assessing the incremental contribution of common genomic variants to melanoma risk prediction in two population-based studies.
    J Invest Dermatol. 2018 Jun 8. pii: S0022-202X(18)32046.
    PubMed     Abstract available

    May 2018
  68. RAMANI V, Teshima T, Tamura K, Chung JS, et al
    Melanoma-derived Soluble DC-HIL/GPNMB Promotes Metastasis by Excluding T-lymphocytes from the Pre-metastatic Niches.
    J Invest Dermatol. 2018 May 29. pii: S0022-202X(18)31987.
    PubMed     Abstract available

  69. NAWAZ A, Wong TW
    Chitosan-carboxymethyl-5-fluorouracil-folate conjugate particles: Microwave modulated uptake by skin and melanoma cells.
    J Invest Dermatol. 2018 May 29. pii: S0022-202X(18)31985.
    PubMed     Abstract available

  70. SEITZ-ALGHROUZ R, Hidalgo JV, Kayser C, Kreutz C, et al
    BRAF V600E Mutations in Nevi and Melanocytic Tumors of Uncertain Malignant Potential (MELTUMPs).
    J Invest Dermatol. 2018 May 15. pii: S0022-202X(18)31973.

  71. THOMAS NE, Edmiston SN, Orlow I, Kanetsky PA, et al
    Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.
    J Invest Dermatol. 2018 May 9. pii: S0022-202X(18)31962.
    PubMed     Abstract available

  72. OLSEN CM, Pandeya N, Thompson BS, Dusingize JC, et al
    Physician skin checks before the diagnosis of melanoma correlate with tumor characteristics.
    J Invest Dermatol. 2018 May 4. pii: S0022-202X(18)31952.

    April 2018
  73. NORDLINGER A, Dror S, Elkahloun A, Del Rio J, et al
    Mutated MITF-E87R in Melanoma Enhances Tumor Progression via S100A4.
    J Invest Dermatol. 2018 Apr 18. pii: S0022-202X(18)31873.
    PubMed     Abstract available

    March 2018
  74. YANG Y, Guo W, Ma J, Xu P, et al
    Down-regulated TRPV1 expression contributes to melanoma growth via calcineurin-ATF3-p53 pathway.
    J Invest Dermatol. 2018 Mar 23. pii: S0022-202X(18)31748.
    PubMed     Abstract available

  75. PANDEYA N, Kvaskoff M, Olsen CM, Green AC, et al
    Factors related to nevus-associated cutaneous melanoma: a case-case study.
    J Invest Dermatol. 2018 Mar 7. pii: S0022-202X(18)30204.
    PubMed     Abstract available

  76. NEAL DE, Derwae AL, Etzkorn JR
    Cells to Surgery Quiz: March 2018.
    J Invest Dermatol. 2018;138:e33.

  77. GADDIS K, Chu EY
    SnapshotDx Quiz: March 2018.
    J Invest Dermatol. 2018;138:e31.

    February 2018
  78. SOLER-CARDONA A, Forsthuber A, Lipp K, Ebersberger S, et al
    CXCL5 facilitates melanoma cell-neutrophil interaction and lymph node metastasis.
    J Invest Dermatol. 2018 Feb 20. pii: S0022-202X(18)30125.
    PubMed     Abstract available

  79. LIN J, Zhang D, Fan Y, Chao Y, et al
    Regulation of cancer stem cell self-renewal by HOXB9 antagonizes ER stress-induced melanoma cell apoptosis via the miR-765-FOXA2 axis.
    J Invest Dermatol. 2018 Feb 3. pii: S0022-202X(18)30105.
    PubMed     Abstract available

  80. TUCKER MA, Elder DE, Curry M, Fraser MC, et al
    Risks of melanoma and other cancers in melanoma-prone families over four decades.
    J Invest Dermatol. 2018 Feb 2. pii: S0022-202X(18)30102.
    PubMed     Abstract available

  81. ELIADES P, Abraham BJ, Ji Z, Miller DM, et al
    High MITF Expression is Associated with Super-enhancers and Suppressed by CDK7 Inhibition in Melanoma.
    J Invest Dermatol. 2018 Feb 2. pii: S0022-202X(18)30106.
    PubMed     Abstract available

  82. CARRERA C, Puig-Butille JA
    Clinical, Epidemiological, and Molecular Heterogeneity in Acral Melanoma.
    J Invest Dermatol. 2018;138:254-255.
    PubMed     Abstract available

  83. BEAULIEU D, Nijhawan RI
    Cells to Surgery Quiz: February 2018.
    J Invest Dermatol. 2018;138:e21.

    January 2018
  84. FAIAO-FLORES F, Smalley KSM
    Get with the Program! Stemness and Reprogramming in Melanoma Metastasis.
    J Invest Dermatol. 2018;138:10-13.
    PubMed     Abstract available

    December 2017
  85. OGAWA H, Luxardi G, Kirane A, Kulkarni R, et al
    T cells dominate the local immune response induced by intralesional IL-2 in combination with imiquimod and retinoid for in-transit metastatic melanoma.
    J Invest Dermatol. 2017 Dec 29. pii: S0022-202X(17)33369.

  86. CONIC RZ, Arbesman J
    Melanoma Tumor Characteristics: An Analysis of Mutational Burden and Copy Number Alterations by Patient Age and Stage.
    J Invest Dermatol. 2017 Dec 5. pii: S0022-202X(17)33236.

  87. KASUMOVA GG, Haynes AB, Boland GM
    Lymphatic versus Hematogenous Melanoma Metastases: Support for Biological Heterogeneity without Clear Clinical Application.
    J Invest Dermatol. 2017;137:2466-2468.
    PubMed     Abstract available

  88. CHHABRA G, Wojdyla L, Frakes M, Schrank Z, et al
    Mechanism of action of G-quadruplex forming oligonucleotide homologous to the telomere overhang in melanoma.
    J Invest Dermatol. 2017 Dec 1. pii: S0022-202X(17)33229.
    PubMed     Abstract available

    November 2017
  89. MOON KR, Choi YD, Kim JM, Jin S, et al
    Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features.
    J Invest Dermatol. 2017 Nov 27. pii: S0022-202X(17)33225.
    PubMed     Abstract available

  90. LIU SM, Lin CH, Lu J, Lin IY, et al
    miR-596 modulates melanoma growth by regulating cell survival and death.
    J Invest Dermatol. 2017 Nov 25. pii: S0022-202X(17)33172.
    PubMed     Abstract available

  91. WANG YF, Liu F, Sherwin S, Farrelly M, et al
    Cooperativity of HOXA5 and STAT3 is critical for HDAC8 inhibition-mediated transcriptional activation of PD-L1 in human melanoma cells.
    J Invest Dermatol. 2017 Nov 22. pii: S0022-202X(17)33164.
    PubMed     Abstract available

  92. LOHCHAROENKAL W, Das Mahapatra K, Pasquali L, Crudden C, et al
    Genome-wide screen for microRNAs reveals a role for miR-203 in melanoma metastasis.
    J Invest Dermatol. 2017 Nov 2. pii: S0022-202X(17)33137.
    PubMed     Abstract available

    October 2017
  93. RUBEL F, Kern JS, Technau-Hafsi K, Uhrich S, et al
    Indoleamine 2,3-dioxygenase expression in primary cutaneous melanoma correlates with Breslow thickness and is of significant prognostic value for progression-free survival.
    J Invest Dermatol. 2017 Oct 17. pii: S0022-202X(17)33059.
    PubMed     Abstract available

    September 2017
  94. HEPPT MV, Wang JX, Hristova DM, Wei Z, et al
    MSX1-induced neural crest-like reprogramming promotes melanoma progression.
    J Invest Dermatol. 2017 Sep 16. pii: S0022-202X(17)32807.
    PubMed     Abstract available

  95. HAO J, Xu H, Luo M, Yu W, et al
    The tumor-promoting role of TRIP4 in melanoma progression and its involvement in response to BRAF-targeted therapy.
    J Invest Dermatol. 2017 Sep 9. pii: S0022-202X(17)32937.
    PubMed     Abstract available

  96. YU B, Alboslemy T, Safadi F, Kim MH, et al
    Glycoprotein non-melanoma clone B regulates the crosstalk between macrophages and mesenchymal stem cells towards wound repair.
    J Invest Dermatol. 2017 Sep 9. pii: S0022-202X(17)32934.
    PubMed     Abstract available

  97. HAUGH AM, Zhang B, Quan VL, Garfield EM, et al
    Distinct Patterns of Acral Melanoma Based on Site and Relative Sun Exposure.
    J Invest Dermatol. 2017 Sep 1. pii: S0022-202X(17)32917.
    PubMed     Abstract available

    August 2017
  98. DONOVAN P, Dubey OA, Kallioinen S, Rogers KW, et al
    Paracrine Activin-A signaling promotes melanoma growth and metastasis through immune evasion.
    J Invest Dermatol. 2017 Aug 24. pii: S0022-202X(17)32820.
    PubMed     Abstract available

  99. DELYON J, Chevret S, Jouary T, Dalac S, et al
    STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network.
    J Invest Dermatol. 2017 Aug 23. pii: S0022-202X(17)32802.
    PubMed     Abstract available

  100. THOMAS NE, Edmiston SN, Kanetsky PA, Busam KJ, et al
    Associations of MC1R genotype and patient phenotypes with BRAF and NRAS mutations in melanoma.
    J Invest Dermatol. 2017 Aug 22. pii: S0022-202X(17)32791.
    PubMed     Abstract available

  101. VON SCHUCKMANN LA, Smith D, Hughes MCB, Malt M, et al
    Associations of statins and diabetes with diagnosis of ulcerated cutaneous melanoma.
    J Invest Dermatol. 2017 Aug 22. pii: S0022-202X(17)32797.
    PubMed     Abstract available

  102. TAYLOR NJ, Mitra N, Goldstein AM, Tucker MA, et al
    Germline variation at CDKN2A and associations with nevus phenotypes among members of melanoma families.
    J Invest Dermatol. 2017 Aug 19. pii: S0022-202X(17)32759.
    PubMed     Abstract available

    July 2017
  103. DAI W, Xu X, Li S, Ma J, et al
    SOX4 promotes proliferative signals by regulating glycolysis through AKT activation in melanoma cells.
    J Invest Dermatol. 2017 Jul 28. pii: S0022-202X(17)32684.
    PubMed     Abstract available

  104. ISHIDA Y, Otsuka A, Tanaka H, Levesque MP, et al
    HLA-A*26 is correlated with response to nivolumab in Japanese melanoma patients.
    J Invest Dermatol. 2017 Jul 20. pii: S0022-202X(17)31863.

  105. CLARKE CA, McKinley M, Hurley S, Haile RW, et al
    Continued increase in melanoma incidence across all socioeconomic status groups in California, 1998-2012.
    J Invest Dermatol. 2017 Jul 20. pii: S0022-202X(17)31867.
    PubMed     Abstract available

  106. GASSENMAIER M, Eigentler TK, Keim U, Goebeler M, et al
    Serial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry.
    J Invest Dermatol. 2017 Jul 20. pii: S0022-202X(17)31871.
    PubMed     Abstract available

    June 2017
  107. VAN TUYN J, Jaber-Hijazi F, MacKenzie D, Cole JJ, et al
    Oncogene-Expressing Senescent Melanocytes Upregulate Mhc Class Ii, A Candidate Melanoma Suppressor Function.
    J Invest Dermatol. 2017 Jun 21. pii: S0022-202X(17)31662.
    PubMed     Abstract available

  108. ASGARI MM, Chien AJ, Tsai AL, Fireman B, et al
    Association between lithium use and melanoma risk and mortality: A population-based study.
    J Invest Dermatol. 2017 Jun 16. pii: S0022-202X(17)31644.
    PubMed     Abstract available

  109. THEODOSAKIS N, Micevic G, Langdon CG, Ventura A, et al
    p90RSK blockade inhibits dual BRAF and MEK inhibitor-resistant melanoma by targeting protein synthesis.
    J Invest Dermatol. 2017 Jun 6. pii: S0022-202X(17)31603.
    PubMed     Abstract available

    May 2017
  110. BUSTOS MA, Ono S, Marzese DM, Oyama T, et al
    MiR-200a Regulates CDK4/6 Inhibitor Effect by targeting CDK6 in Metastatic Melanoma.
    J Invest Dermatol. 2017 May 16. pii: S0022-202X(17)31528.
    PubMed     Abstract available

  111. SHI Q, Liu H, Han P, Li C, et al
    Genetic Variants in WNT2B and BTRC Predict Melanoma Survival.
    J Invest Dermatol. 2017 May 9. pii: S0022-202X(17)31489.
    PubMed     Abstract available

  112. LEITER U, Keim U, Eigentler T, Katalinic A, et al
    Incidence, Mortality and Trends of Non-Melanoma Skin Cancer in Germany.
    J Invest Dermatol. 2017 May 6. pii: S0022-202X(17)31482.
    PubMed     Abstract available

  113. BAUER J
    The Molecular Revolution in Cutaneous Biology: Era of Cytogenetics and Copy Number Analysis.
    J Invest Dermatol. 2017;137:e57-e59.
    PubMed     Abstract available

    April 2017
  114. FANG S, Wang Y, Dang Y, Gagel A, et al
    Association between body mass index, C-reactive protein levels, and melanoma patient outcomes.
    J Invest Dermatol. 2017 Apr 22. pii: S0022-202X(17)31423.

  115. KIM SH, Li M, Trousil S, Zhang Y, et al
    Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma.
    J Invest Dermatol. 2017 Apr 19. pii: S0022-202X(17)31420.
    PubMed     Abstract available

  116. SEO EY, Jin SP, Sohn KC, Park CH, et al
    UCHL1 Regulates Melanogenesis through Controlling MITF Stability in Human Melanocytes.
    J Invest Dermatol. 2017 Apr 6. pii: S0022-202X(17)31396.
    PubMed     Abstract available

  117. SFECCI A, Dupuy A, Dinulescu M, Droitcourt C, et al
    Do the Side Effects of BRAF Inhibitors Mimic RASopathies?
    J Invest Dermatol. 2017;137:805-809.
    PubMed     Abstract available

    February 2017
  118. PUIG-BUTILLE JA, Vinyals A, Ferreres JR, Aguilera P, et al
    AURORA A overexpression (AURKA) is driven by FOXM1 and MAPK/ERK activation in melanoma cells harbouring BRAF or NRAS mutations: Impact on melanoma prognosis and therapy.
    J Invest Dermatol. 2017 Feb 7. pii: S0022-202X(17)30115.
    PubMed     Abstract available

  119. ZHOU Y, Tripathi SV, Rosman I, Ma J, et al
    Noninvasive Determination of Melanoma Depth using a Handheld Photoacoustic Probe.
    J Invest Dermatol. 2017 Feb 2. pii: S0022-202X(17)30104.

    January 2017
  120. TROUSIL S, Chen S, Mu C, Shaw FM, et al
    Phenformin enhances the efficacy of ERK inhibition in NF1-mutant melanoma.
    J Invest Dermatol. 2017 Jan 28. pii: S0022-202X(17)30052.
    PubMed     Abstract available

  121. TSAO H, Fukunaga-Kalabis M, Herlyn M
    Recent Advances in Melanoma and Melanocyte Biology.
    J Invest Dermatol. 2017 Jan 12. pii: S0022-202X(16)32640.

    December 2016
  122. ROOS L, Sandling JK, Bell CG, Glass D, et al
    Higher Naevus Count Exhibits A Distinct DNA Methylation Signature in Healthy Human Skin: Implications for Melanoma.
    J Invest Dermatol. 2016 Dec 16. pii: S0022-202X(16)32787.
    PubMed     Abstract available

  123. KAWAKAMI A, Fisher DE
    Bioinformatic Analysis of Gene Expression for Melanoma Treatment.
    J Invest Dermatol. 2016;136:2342-2344.
    PubMed     Abstract available

    November 2016
  124. MELAMED RD, Aydin IT, Rajan GS, Phelps R, et al
    Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma.
    J Invest Dermatol. 2016 Nov 24. pii: S0022-202X(16)32663.
    PubMed     Abstract available

  125. CHIANG NY, Peng YM, Juang HH, Chen TC, et al
    GPR56/ADGRG1 activation promotes melanoma cell migration via NTF dissociation and CTF-mediated Galpha12/13/RhoA signaling.
    J Invest Dermatol. 2016 Nov 3. pii: S0022-202X(16)32618.
    PubMed     Abstract available

    October 2016
  126. KOHLI JS, Tolomio E, Frigerio S, Maurichi A, et al
    Common Delayed Senescence of Melanocytes from Multiple Primary Melanoma Patients.
    J Invest Dermatol. 2016 Oct 28. pii: S0022-202X(16)32610.

  127. ELIADES P, Tsao H
    New Insights into the Molecular Distinction of Dysplastic Nevi and Common Melanocytic Nevi-Highlighting the Keratinocyte-Melanocyte Relationship.
    J Invest Dermatol. 2016;136:1933-5.
    PubMed     Abstract available

    September 2016
  128. VIARISIO D, Muller-Decker K, Hassel JC, Alvarez JC, et al
    The BRAF inhibitor vemurafenib enhances UV-induced skin carcinogenesis in beta HPV38 E6 and E7 transgenic mice.
    J Invest Dermatol. 2016 Sep 17. pii: S0022-202X(16)32449.

  129. LUCARINI V, Buccione C, Ziccheddu G, Peschiaroli F, et al
    Combining Type I Interferons and 5-Aza-2'-Deoxycitidine to improve anti-tumor response against melanoma.
    J Invest Dermatol. 2016 Sep 10. pii: S0022-202X(16)32368.
    PubMed     Abstract available

    July 2016
  130. WEIDE B, Schafer T, Martens A, Kuzkina A, et al
    High GDF-15 serum levels independently correlate with poorer overall survival of tumor-free stage III and unresectable stage IV melanoma patients.
    J Invest Dermatol. 2016 Jul 22. pii: S0022-202X(16)32125.
    PubMed     Abstract available

    May 2016
  131. POSCH C, Sanlorenzo M, Vujic I, Oses-Prieto JA, et al
    Phospho-proteomic analyses of NRAS(G12) and NRAS(Q61) mutant melanocytes reveal increased CK2alpha kinase levels in NRAS(Q61) mutant cells.
    J Invest Dermatol. 2016 May 29. pii: S0022-202X(16)31261.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.